期刊
LANGENBECKS ARCHIVES OF SURGERY
卷 393, 期 1, 页码 93-104出版社
SPRINGER
DOI: 10.1007/s00423-007-0230-1
关键词
colorectal cancer; biomarkers; genomics; transcriptomics; proteomics
类别
资金
- NATIONAL CANCER INSTITUTE [Z01BC010837, ZIABC010836, Z01BC010833, ZIABC010835, ZIABC010833, Z01BC010836, Z01BC010835, ZIABC010837] Funding Source: NIH RePORTER
Background and aims Colorectal cancer is the second leading cause of cancer-related death. Current clinical practice in colorectal cancer screening (fecal occult blood test, FOBT; colonoscopy) has contributed to a reduction of mortality. However, despite these screening programs, about 70% of carcinomas are detected at advanced tumor stages (UICC III/IV) presenting poor patient prognosis. Thus, innovative tools and methodologies for early cancer detection can directly result in improving patient survival rates. Patients/methods Biomedical research has advanced rapidly in recent years with the availability of technologies such as global gene and protein expression profiling. Comprehensive tumor profiling has become a field of intensive research aiming at identifying biomarkers relevant for improved diagnostics and therapeutics. Results In this paper, we report a comprehensive review of genomic, transcriptomic, and proteomic approaches for biomarker identification in tissue and blood with a main emphasis on two-dimensional gel-electrophoresis (2-DE) and mass spectrometry analyses. Conclusion Proteomics-based technologies enable to distinguish the healthy patient from the tumor patient with high sensitivity and specificity and could greatly improve common classification systems and diagnostics. However, this progress has not yet been transferred from bench to bedside but could open the door to a more accurate and target specific personalized medicine with improved patient survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据